185 related articles for article (PubMed ID: 35969350)
21. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
22. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.
Han L; Shi H; Luo Y; Sun W; Li S; Zhang N; Jiang X; Gong Y; Xie C
Cancer Med; 2020 Dec; 9(24):9581-9594. PubMed ID: 33098370
[TBL] [Abstract][Full Text] [Related]
23. Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma.
Li P; Che S; Qi Y; Luo N; Lin Q; Zhu X; Xuan Y; Li M; Li J; Ge M; Sun T; Qi C; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2997-3007. PubMed ID: 35838838
[TBL] [Abstract][Full Text] [Related]
24. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
25. Profiles of Immune Infiltration and Prognostic Immunoscore in Lung Adenocarcinoma.
Li Y; Tao L; Cai W
Biomed Res Int; 2020; 2020():5858092. PubMed ID: 32596334
[TBL] [Abstract][Full Text] [Related]
26. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
27. CD8
Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H
Front Immunol; 2022; 13():806877. PubMed ID: 35273597
[TBL] [Abstract][Full Text] [Related]
28. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
29. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
30. A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma.
Xu F; Zhan X; Zheng X; Xu H; Li Y; Huang X; Lin L; Chen Y
Genomics; 2020 Nov; 112(6):4675-4683. PubMed ID: 32798715
[TBL] [Abstract][Full Text] [Related]
31. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
32. Deciphering N
Zhu J; Wang M; Hu D
Biomed Res Int; 2020; 2020():2514230. PubMed ID: 32258108
[TBL] [Abstract][Full Text] [Related]
33. GPX8
Bai Y; Han T; Dong Y; Liang C; Gao L; Liu Y; Zhou J; Guo J; Ge D; Wu J; Hu D
BMC Med Genomics; 2024 Mar; 17(1):77. PubMed ID: 38515109
[TBL] [Abstract][Full Text] [Related]
34. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
35. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
Front Immunol; 2022; 13():960738. PubMed ID: 36032135
[TBL] [Abstract][Full Text] [Related]
36. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
[TBL] [Abstract][Full Text] [Related]
37. Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma.
Yang W; Wu Z; Cai S; Li Z; Wang W; Wu J; Luo H; Ye X
Front Immunol; 2024; 15():1354339. PubMed ID: 38638428
[TBL] [Abstract][Full Text] [Related]
38. Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma.
Zhang P; Pei S; Wu L; Xia Z; Wang Q; Huang X; Li Z; Xie J; Du M; Lin H
Front Endocrinol (Lausanne); 2023; 14():1196372. PubMed ID: 37265698
[TBL] [Abstract][Full Text] [Related]
39. A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma.
Zhang Y; Wang Y; Chen J; Xia Y; Huang Y
Front Immunol; 2023; 14():1183230. PubMed ID: 37671155
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
